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Summary
An increasing number of aging researchers believes that multi-
system physiological dysregulation may be a key biological
mechanism of aging, but evidence of this has been sparse. Here,
we used biomarker data on nearly 33 000 individuals from four
large datasets to test for the presence of multi-system dysregu-
lation. We grouped 37 biomarkers into six a priori groupings
representing physiological systems (lipids, immune, oxygen
transport, liver function, vitamins, and electrolytes), then calcu-
lated dysregulation scores for each system in each individual
using statistical distance. Correlations among dysregulation
levels across systems were generally weak but significant.
Comparison of these results to dysregulation in arbitrary ‘sys-
tems’ generated by random grouping of biomarkers showed that
a priori knowledge effectively distinguished the true systems in
which dysregulation proceeds most independently. In other
words, correlations among dysregulation levels were higher
using arbitrary systems, indicating that only a priori systems
identified distinct dysregulation processes. Additionally, dysreg-
ulation of most systems increased with age and significantly
predicted multiple health outcomes including mortality, frailty,
diabetes, heart disease, and number of chronic diseases. The six
systems differed in how well their dysregulation scores predicted
health outcomes and age. These findings present the first
unequivocal demonstration of integrated multi-system physio-
logical dysregulation during aging, demonstrating that physio-
logical dysregulation proceeds neither as a single global process
nor as a completely independent process in different systems, but
rather as a set of system-specific processes likely linked through
weak feedback effects. These processes – probably many more
than the six measured here – are implicated in aging.
Key words: aging; biomarker; homeostasis; multi-system
dysregulation; physiology; statistical distance.
Introduction
Research on aging biomarkers has traditionally focused on individual
biomarkers; however, this has been changing as single-mechanism
explanations of aging such as oxidative stress, telomeres, and inflamma-
tion increasingly give way to multi-factorial explanations, in which many
mechanisms interact (Weinert & Timiras, 2003; Ferrucci, 2005; Fried et al.,
2009; Cohen et al., 2013). In particular, much attention is focusing on
physiological dysregulation (alternatively referred to as allostatic load or
homeostenosis) (McEwen, 1998; Karlamangla et al., 2002; Crimmins
et al., 2003). While evidence is abundant for increases in various types of
physiological dysfunction with age, our use of ‘dysregulation’ is more
restricted, as an emergent property of a complex system in the formal
sense (Holland, 1992; Kauffman, 1993; Kriete, 2013). We define
physiological dysregulation as the breakdown with age in the capacity
of the complex regulatory networks to maintain organismal homeostasis
due to changes in the state of these networks; we exclude from this
definition adaptive changes with age and transient (i.e., reversible)
responses to environmental challenges (Yashin et al., 2012).
This framework of homeostatic dysregulation supports the hypothesis
that aging does not result from the downstream effects of a single
factor, pathway, or process. Rather it suggests the following testable
predictions: (i) multiple aging mechanisms should operate simultane-
ously; there could be several or many pathways, either independent or
correlated (Kirkwood, 2005); (ii) markers of system state should be
poorer predictors of aging-related outcomes than measures of system
dynamics (Varadhan et al., 2008; Yashin et al., 2010a); and (iii) risk of
aging-related outcomes (e.g., diseases) should often change as a
function of deviations of parameters (e.g., biomarkers) from their
normal ranges, rather than as a linear function of the parameters
(Seplaki et al., 2005; Arbeev et al., 2011; Yashin et al., 2012; Cohen
et al., 2013).
While these predictions are intuitive, they are hard to test and
evidence has largely been lacking, in large part due to the difficulties in
measuring dysregulation. Clearly, many studies have shown that
physiological parameters change with age, and many of these changes
are associated with specific pathologies or age-related problems (e.g.,
Seplaki et al., 2005). In this sense, there has long been good evidence
for functional changes during aging. However, theories on homeostatic
dysregulation suggest that dysregulation is not a piece-by-piece set of
problems that accumulate, but rather a breakdown in the functioning of
a complex system such that the overall functional deficits cannot be
simply or directly linked to specific piecewise problems. Perhaps the best
evidence to date has come from two key studies: Lipsitz (2004) has
demonstrated that declines in complexity of traits like heart rate
variability are linked to aging, and Fried et al. (2009) showed coordi-
nated, non-linear changes with age in biomarkers representing several
physiological systems.
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Recently, we demonstrated a novel, rigorous way to measure
dysregulation based on the statistical distance of a biomarker profile
(Cohen et al., 2013, 2014; Milot et al., 2014b). Statistical distance
assigns a score for how far an individual’s profile is from the average
profile; under a hypothesis of dysregulation, high scores indicate more
dysregulation, and should thus increase with age and predict health
outcomes after controlling for age. Furthermore, dysregulation is
expected to be a higher order property of regulatory networks, and
thus not overly sensitive to the choice of biomarkers (Cohen et al.,
2013). These predictions have been confirmed in different human
populations and species (Cohen et al., 2014; Milot et al., 2014a);
however, it is not yet clear to what extent dysregulation might be a
single global process, vs. a process that occurs independently or semi-
independently in different physiological systems which then further
dysregulate each other. We might intuitively suspect that aging proceeds
separately in different systems, but there are many known regulatory
links across systems. For example, vitamin E plays roles in both the
immune system and oxidative balance; many hormones coordinate
activity across multiple systems; and relative levels of albumin and
anemia appear to be coordinated (Cohen et al., 2012, 2015b).
Additionally, the relative insensitivity of global dysregulation measures
to biomarker composition gives the impression that dysregulation during
aging might be best characterized as a single global process rather than
a system-by-system process (Cohen et al., 2013, 2014). This paper
investigates that question.
Here, we tested the relationships of dysregulation scores among
different physiological systems using data on 37 common clinical blood
biomarkers in four well-known datasets, the National Health and
Nutrition Examination Survey (NHANES), the Women’s Health and
Aging Study (WHAS), the Baltimore Longitudinal Study on Aging
(BLSA), and Invecchiare in Chianti (Aging in Chianti, InCHIANTI).
Biomarkers were grouped into six standard physiological systems,
which we call the ‘a priori groupings’ (Table 1): immune function (five
biomarkers), electrolytes (five biomarkers), vitamins (seven biomarkers),
oxygen transport/anemia (eight biomarkers), lipids (four biomarkers),
and liver/kidney/protein transport (eight biomarkers). We examined
correlations among dysregulation levels of the a priori groupings to
assess whether dysregulation rates are similar across physiological
systems. To assess whether the a priori groupings optimally reflected
the true underlying systems, we compared the correlations among
them to correlations among randomly generated biomarker groupings
(the ‘arbitrary groupings’), predicting lower correlations among dysreg-
ulation scores for groupings that better distinguished independent
systems. If dysregulation proceeds completely independently across
systems, correlations among dysregulation scores should be zero after
age-adjustment. Conversely, if there is a single, global dysregulatory
process, dysregulation scores based on the a priori groupings should
correlate as strongly among each other as based on the arbitrary
groupings, and none of these correlations should be weak. We
replicated our analyses across the four datasets and tested the
associations of each system-specific dysregulation with age, mortality,
and various health outcomes.
Results
Dysregulation in a priori physiological systems
For each of the six physiological systems, we calculated a dysregulation
score based on the Mahalanobis distance (see Experimental procedures)
to measure dysregulation for each participant at each visit. Then we
adjusted the system-specific dysregulation scores for age and calculated
the pairwise Pearson correlations among these residuals. This resulted in
the 15 correlations in Fig. 1. We found weak but mostly significant
correlations among dysregulation levels for the a priori groupings
(Fig. 1). When significant, correlations were always positive, and never
greater than r = 0.27. Five correlations were significant in all data sets
where they were tested, and two were significant in no data set (Fig. 1).
The results in Fig. 1 are age-adjusted (see Experimental procedures) but
results without adjusting for age lead to the same conclusion (Fig. S1,
Supporting Information).
Correlations among a priori biomarker groupings compared
with correlations among arbitrary biomarker groupings
If the a priori groupings accurately identify true physiological systems
with respect to dysregulation, and if dysregulation proceeds at least
semi-independently in these systems, we expect weaker correlations
among dysregulation scores of the a priori groupings compared to
arbitrary groupings of biomarkers. This is because arbitrary groupings
would mix biomarkers across physiological systems, and therefore make
them less distinct and more correlated. Accordingly, testing the pairwise
correlations among all possible combinations of biomarkers vs. the a
priori groups allows us to assess not only whether there is separate
dysregulation across systems, but whether our a priori groupings are
representative, or whether there might be other hidden or non-intuitive
groupings of biomarkers that better represent the underlying dysregu-
lation processes.
For each of the 15 pairwise combinations of the six physiological
systems, we generated all possible biomarker groupings in two groups
of equal size to the original two groups. For example, we had five
electrolyte markers and four lipid markers, so for this pair we
generated all possible combinations for two groups of five and four
markers, respectively, 9 choose 5 = 9!/5!*(9–5)! = 126. However, we
did not use groups with different sizes than the original (e.g., 6 and 3)
to insure apples-to-apples comparisons. For each combination, we
calculated the correlation between individuals’ age-adjusted dysregu-
lation scores as calculated for each biomarker group and compared this
to the correlation between individuals’ dysregulation scores of the two
original (a priori) biomarker groups (Fig. 2). To better visualize the
results across the four datasets in a single panel, we show the kernel
densities of the distributions of the correlations among the arbitrary
groupings for each data set, and the vertical lines indicate the
correlations for the a priori grouping. The vertical lines are almost
always toward the extreme left of the distribution of correlations,
indicating that the a priori groupings separated physiological systems
about as well as possible. Note also that the kernel density distributions
were generally concordant across datasets, but varied across the 15
pairs of systems.
However, our a priori groupings rarely produced the single most
optimal division, i.e., the combination with the lowest correlation.
Close examination of results revealed that this was because some
markers have a strong affinity for one group or the other (e.g., the
blood biomarkers hemoglobin, hematocrit, MCH, MCHC, red blood cell
count, and RDW always group strongly), whereas other markers are
not strongly associated with either group, and can thus be placed
about equally well in either. Nonetheless, the performance of the
optimal groups was never much better than the a priori groupings; for
this reason, we believe that the a priori groupings are representative of
their physiological systems and we used these a priori groupings in
subsequent analyses.
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Association of dysregulation with age
Next, we calculated the association of system-specific and global
dysregulation with age for the three datasets that have longitudinal
data, namely InCHIANTI, WHAS, and BLSA (Fig. 3). Dysregulation
increased with age for most of the physiological systems in most data
sets, with the exception of lipids in BLSA, where the slope was negative
but not significant. All other results were positive although a few
(dashed lines) were not significant. The quadratic term was always
significant for InCHIANTI and sometimes significant for BLSA; the
significant quadratic trajectories (J-shaped) of dysregulation indicate an
acceleration of dysregulation with age. In the same figure, we also
show the result based on all of the 37 biomarkers (the last panel in
Fig. 3), i.e., the association of a ‘global’ dysregulation with age; the
results were always reproducible across the datasets and there do not
appear to be marked differences in the rate of increase across systems,
other than the potential absence of a relationship with age for lipid
dysregulation.
The effects of dysregulation on mortality and other health
outcomes
Finally, we explored the association of system-specific and global
dysregulation with mortality, clinical frailty, number of comorbidities,
cardiovascular disease, cancer, and diabetes (Fig. 4) in the two datasets
where the relevant information was available (InCHIANTI and WHAS), as
done previously for global dysregulation on a subset of markers (Milot
et al., 2014b). Depending on data availability, we examined either cross-
Table 1 A priori biomarker groupings and summary statistics by dataset
Biomarker System
Women’s Health and
Aging Study InCHIANTI
Baltimore
Longitudinal Study
on Aging
National Health and
Nutrition
Examination Survey
Mean SD Mean SD Mean SD Mean SD
Calcium Electrolytes 9.5 0.5 9.4 0.5 9.3 0.4 9.5 0.39
Chloride Electrolytes 103 4 106 4 104 3 103 2.84
Magnesium Electrolytes 1.99 0.20 2.08 0.36 2.05 0.20 NA NA
Sodium Electrolytes 140.0 2.9 141.2 2.9 141.7 2.8 139 2.34
Potassium Electrolytes 4.2 0.43 4.19 0.40 4.20 0.34 4 0.34
Phosphorous Electrolytes NA NA NA NA NA NA 3.9 0.65
Hemoglobin Blood measures 13.0 1.2 13.8 1.5 13.6 1.4 14 1.51
Hematocrit Blood measures 39 4 41 4 41 4 41 4.41
Iron Blood measures 80 27 85 29 89 32 86 36.5
Red cell distribution width Blood measures 14.1 1.4 13.8 1.2 13.5 1.5 13 1.14
MCH Blood measures 30.5 2.1 30.5 2.1 30.4 2.1 30 2.34
MCHC Blood measures 33.1 1.2 33.7 1.0 33.5 1.2 34 0.91
Ferritin Blood measures 112 124 123 127 107 99 81 118
Red blood cell count Blood measures 4.26 0.43 4.53 0.47 4.50 0.48 4.7 0.48
Albumin Proteins, liver, kidney 4.1 0.3 58.9 4.2 4.1 0.3 4.3 0.38
Alkaline Phosphatase Proteins, liver, kidney 87 35 165 110 78 23 92 65
Total proteins Proteins, liver, kidney 7.0 0.5 7.3 0.5 7.1 0.5 7.3 0.5
Gamma-glutamyl transpeptidase Proteins, liver, kidney 31 36 27 32 30 24 27 40.3
Lactate dehydrogenase Proteins, liver, kidney 177 35 344 75 430 163 136 34.5
Uric acid Proteins, liver, kidney 5.6 1.7 5.2 1.4 5.3 1.4 5.3 1.43
Alanine transaminase Proteins, liver, kidney 19.6 10.9 20.8 10.5 32.0 12.4 24 24.1
Aspartate transaminase Proteins, liver, kidney 16.2 12.1 19.4 15.2 28.1 10.6 25 17.8
White blood cell count Immune measures 6.3 2.4 6.3 1.7 6.0 3.5 7.3 2.38
Neutrophil Immune measures 60 10 59 9 55 10 55 11.9
Monocytes Immune measures 6.9 2.4 6.6 2.2 9.2 4.3 8 2.39
Lymphocytes Immune measures 29 9 31 8 32 10 33 10.7
Basophils Immune measures 0.74 0.53 0.52 0.35 0.55 0.32 0.7 0.58
Triglycerides Lipids 4.923 0.54 4.73 0.47 4.51 0.49 4.8 0.57
HDL Lipids 3.968 0.29 57.1 15 58.7 17.2 53 16.2
Cholesterol Lipids 224.3 41.3 215 41.8 194 36.5 200 42.9
LDL Lipids NA NA 132 37.1 116 32.9 118 36.2
Cholesterol/HDL ratio Lipids 4.471 1.46 NA NA NA NA NA NA
Vitamin B12 Vitamins 494 307 471 334 NA NA 641 2218
Folate Vitamins 12.4 10.4 10.1 6.9 NA NA 21 10.8
Vitamin A/retinol Vitamins 72.06 23.6 1.94 0.49 NA NA 52 17.6
Gamma-tocopherol Vitamins 10.07 1.13 2.21 0.95 NA NA 224 121
Beta-cryptoxanthin Vitamins 0.148 0.14 0.21 0.16 NA NA 11 8.29
Alpha-carotene Vitamins 0.104 0.1 0.06 0.05 NA NA 3.7 5.33
Vitamin D-25 Vitamins 21.71 10.9 54 36 NA NA 22 8.88
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sectional associations or longitudinal associations; see Experimental
procedures for details.
Dysregulation predicted mortality controlling for age, usually signif-
icantly and quite strongly (Fig. 4a), with each additional unit of
dysregulation score implying about a 30% increase in hazard of
mortality. The sole exception was electrolyte dysregulation in InCHIANTI;
blood, liver, and global dysregulation showed the strongest effects.
Frailty was predicted by electrolyte, blood, and liver dysregulation, and
perhaps weakly by vitamin, lipid, and global dysregulation (Fig. 4b).
Dysregulation was only weakly associated with the number of comor-
bidities, but effects were surprisingly stable across systems and data sets
(Fig. 4c). Cardiovascular disease incidence is strongly predicted by liver,
vitamin and global dysregulation, and more weakly by electrolyte and/or
blood dysregulation in InCHIANTI, but the results do not hold for cross-
sectional analysis of CVD prevalence in WHAS (Fig. 4d). Diabetes
incidence and prevalence are reliably predicted by electrolyte, liver,
lipid, and global dysregulation (Fig. 4e). Cancer was generally unasso-
ciated with dysregulation, with an exception for cancer incidence being
predicted by blood dysregulation in InCHIANTI (Fig. 4f).
Feedback effects among systems
We tested the potential for long-term causal effects among the six
systems, using structural equations models to assess the effect of
dysregulation in each system on all the others at subsequent time points
and controlling for the effect of each dysregulation on itself. Each
system’s dysregulation consistently predicted itself at subsequent time
points (P < 0.0001 for all systems in all data sets), but in no case was
there a clear, reproducible result for dysregulation scores of one system
predicting another in more than two datasets (Table 2). Detailed results
are available in Table S2.
Discussion
Overall, we found strong support for the existence of system-specific
dysregulation processes in all six physiological systems we tested. We
also found semi-independence between the six system-specific
dysregulation processes. A priori definition of these systems by
biomarker groupings was close to optimal within the marker set
available, though some biomarkers did not clearly fall within any system.
Dysregulation of all systems except lipids clearly increased with age, and
in some cases clearly accelerated with age. System-specific dysregulation
scores also predicted a wide variety of health outcomes, though these
associations often depended on which system, which outcome, and
whether the association was analyzed for cross-sectional prevalence or
longitudinal incidence. Mortality and frailty in particular were predicted
independently by dysregulation of most systems. Correlations among
individuals’ dysregulation scores for different systems were mostly
positive but weak, suggesting a model of semi-independence, i.e., that
processes internal to each system cause dysregulation, but with the
possibility for feedback effects with dysregulation of other systems.
This finding has substantial implications for our understanding of the
biological mechanisms of aging. For example, if aging is largely a result
of uniform cellular senescence, we would not expect largely indepen-
dent dysregulation processes in different systems. More likely, cellular
senescence interacts with tissue-, organ-, and organism-level processes
in complex, system-specific ways. In this case, a focus on cellular
senescence alone as the root of aging may be misplaced. Conversely,
while global dysregulation can be measured, it does not appear that
there is a single, organism-level dysregulation process that can explain
aging. Our findings thus support the need to incorporate multiple
hierarchical levels to arrive at a comprehensive understanding of aging.
These findings also present the first unequivocal demonstration of
integrated multi-system physiological dysregulation during aging. While
numerous authors have discussed the possibility of multi-system
dysregulation (Crimmins et al., 2003; Ferrucci, 2005; Seplaki et al.,
2005; Varadhan et al., 2008; Fried et al., 2009; Arbeev et al., 2011;
Maggio et al., 2014), empirical studies have been sparse. Lipsitz has
demonstrated loss of complexity in cardiac rhythms and other aspects of
physiology (Lipsitz, 2004), but the link to dysregulation is still unclear.
Allostatic load studies have quantified what can be interpreted as a
global measure of dysregulation (Karlamangla et al., 2002; Crimmins
et al., 2003; Szanton et al., 2009), comparable to some of our previous
studies using statistical distance. To our knowledge, the only study to
explicitly measure multi-system physiological dysregulation is that of
Fried et al. (2009). In that study, one or two biomarkers per system were
used to define dysregulation based on a priori clinical knowledge;
number of dysregulated systems was then shown to predict clinical
frailty status. Our findings here present a substantial next step: (i) using a
previously validated statistical method to quantitate dysregulation; (ii)
including 4+ markers per system to increase the robustness of the
inference; (iii) independently validating the choice of biomarkers in each
system; (iv) establishing the correlations among dysregulations of
different systems; (v) using longitudinal data to make more robust
temporal inferences; and (vi) explicitly testing the relationship of each
type of dysregulation with age, mortality, and chronic diseases.
The most likely explanation for the weak correlations among
dysregulation scores of different systems is that there are feedback
effects among the systems. We attempted to test for this using the
structural equation models to predict subsequent dysregulation scores
based on current dysregulation scores across systems. While some results
were significant, this proportion was only slightly higher than might be
Fig. 1 Correlations among age-adjusted system-specific dysregulation scores. The
dysregulation scores were calculated from the six a priori biomarker groupings
and then adjusted for age. Darker background color indicates stronger correlation,
and values not significant at a = 0.05 are Xed out. The correlations are positive
and weak in general, showing semi-independence (or very weak dependence) of
the six system-specific dysregulation scores.
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expected by chance given multiple testing issues (Rothman, 1990;
Bender & Lange, 2001), and the relationships we did find were not easily
reproducible across datasets. We see three likely explanations for this
failure to detect clear feedback effects. First, the six systems measured
here are a very small percentage of the actual systems involved in
dysregulation and aging; they are the ones for which sufficient
biomarker data were available in our datasets. It is thus highly likely
that any feedback effects among these six systems are mediated by
other systems that have not been assessed. This would explain why we
do find some significant effects, but inconsistently so across datasets:
contingency could have a large role. Second, timescales could be crucial
here, and perhaps the intervals of several years between the visits
(somewhat variable across datasets) were not the right timescale to
detect the effects we were looking for. Third, there could be some
upstream process causing all the dysregulations, such that they are
correlated but do not cause each other.
Obviously, the 37 biomarkers measured here represent a tiny fraction
of the molecules and systems likely to be implicated in aging (Medvedev,
Fig. 2 Quasi-optimal separation of systems with a priori groups. The solid curves show the kernel densities by dataset of the correlation coefficients between two age-
adjusted dysregulation scores as calculated from all possible arbitrary biomarker groupings with the same sizes as the two a priori groups. Positions of the vertical dotted lines
indicate correlations among the two age-adjusted dysregulation scores corresponding to the a priori biomarker groupings, i.e., the results presented in Fig. 1. Each panel
shows a possible pair of two systems. Different colors are used for different datasets. The figure shows that a priori biomarker groupings lead to much more weakly
correlated dysregulation scores than arbitrary groupings and are close to as perfectly separated as possible, although a few correlations in the distribution are as low as the a
priori correlations.
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1990; Kirkwood, 2011). Similar methods can likely be applied to high-
throughput technologies such as microarray, proteome, and metabo-
lome data to identify other important systems (e.g., Hoffman et al.,
2014). Nonetheless, circulating blood biomarkers should provide much
of the most important information: organism-level signaling occurs
mostly through the circulatory and central nervous systems, and many of
the classical biomarkers are critical regulatory molecules with broad
roles, or are well-known to be good general indicators of health state.
Moreover, our previous studies show that the signal of dysregulation
appears to get stronger as more markers are included, but with
diminishing returns for additional markers (Cohen et al., 2013, 2014). At
this point, we do not feel there is sufficient evidence to thoroughly
explore the implications of our findings system-by-system. However,
long term our hope is that the approach we describe can be used to
gradually work down from the organism level to physiological systems,
organs, tissues, and cells. This is another advantage of our approach
relative to other methods of measuring allostatic load or organism state:
we provide a pathway toward linking an organismal understanding to
more detailed mechanistic studies.
The presence of global and system-specific dysregulation, as mea-
sured by statistical distance, supports a complex systems theory of aging
in which individual molecules play minor roles in determining overall
system state and behavior (Ferrucci, 2005; Managbanag et al., 2008;
Fried et al., 2009; Cohen et al., 2013). Under this theory, aging is at
least partly due to emergent properties of complex system dynamics.
This is further strengthened by the robustness of dysregulation measures
to the inclusion or exclusion of individual biomarkers. Correlations of
individual biomarkers with age vary substantially across populations and
must be interpreted with caution (Cohen et al., 2015b); likewise, the
same biomarker can have both pro- and anti-longevity associations at
different points in the lifespan (Moeller et al., 2014). These findings
might arise because aging involves a mix of non-adaptive (i.e.,
pathological) changes, as well as other compensations to these changes.
This is supported by findings that optimal biomarker levels change with
age (Arbeev et al., 2011). Accordingly, while our results agree with a
complex systems theory of aging, they are not proof of such an
explanation. In particular, we cannot exclude the possibility of an
upstream cause that affects dysregulation in multiple systems.
Likewise, a complex systems understanding of aging and physiology
suggests that targeting individual molecules as key players in aging and
chronic disease will rarely bear fruit; in this context, measures of system-
specific dysregulation will simultaneously provide a big-picture explana-
tion of the physiological underpinnings of aging pathologies and
concrete tools to measure aspects of biological aging rate (Levine,
2013). For example, we can ask how aspects of lifestyle such as diet,
physical activity, and social participation affect dysregulation rates in
different systems, targeting the most critical (such as blood and liver
dysregulation here) for interventions. Quantitation of system-specific
dysregulation thus provides both biological insight into the aging process
and concrete tools to measure aging and improve the health of aging
populations.
Our study must be considered in light of several limitations. First,
statistical distance depends on identifying a ‘normal’ physiological
state, the statistical centroid. This is usually calculated as the
population average for all parameters, a reasonable but imperfect
approximation. It is not easy to find an ideal centroid (Cohen et al.,
2013, 2015a); hence the dysregulation scores could be biased
systematically. Accordingly, further work is needed to estimate a
robust vector of biomarker values to replace the centroid, based not
on the means but, ideally, on age-specific profiles of mortality risk
across biomarker values. Second, the suite of biomarkers used is
neither comprehensive nor the best conceivable. The statistical
methods used are designed to function even with imperfect
biomarkers, but undoubtedly future studies will be necessary to
improve biomarker selection and thereby produce more accurate
results. Third, we do not take genetic background into account. While
genetic factors certainly have some influence on the processes we
seek to describe, genetic control of aging appears largely due to many
genes of small effect (Yashin et al., 2010b), many of which have yet
to be identified, and incorporation into this study would require
stratification into more groups than is feasible. Nevertheless, we
believe that both genetic and sociological influences on aging pass
through the physiological pathways studied here, making them logical
follow-up studies when more information is available.
Experimental procedures
Datasets
Sampling and data collection procedures for the four study populations
are described in detail elsewhere (Shock, 1984; Fried et al., 1995;
Guralnik et al., 1995; Ferrucci et al., 2000; Ferrucci, 2009); we also
provide more detailed information in the Supporting Information. BLSA,
InCHIANTI, and WHAS are longitudinal cohort studies and are composed
of elderly community dwelling adults (BLSA and InCHIANTI contain a
small proportion of young individuals). The sample sizes used for this
Fig. 3 Changes in dysregulation scores with age, by physiological system. The first
six panels show the association between age and dysregulation scores of the
corresponding systems. The last panel shows the association between age and
global dysregulation. We first fitted the quadratic model. If the quadratic term was
significant (a = 0.05), we showed it with a solid quadratic curve. When the
quadratic term was not significant, we fitted the linear model. Significant results
are shown with a solid line and non-significant results with a dashed line. Age
started from 65 for Women’s Health and Aging Study (WHAS) and the other two
datasets had a small fraction of younger patients. The figure indicates a clear
increase of system-specific and global dysregulation scores with age. Note that the
analyses here are longitudinal, so National Health and Nutrition Examination
Survey (NHANES) data were not used.
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study were 2644 visits (1256 patients), 2932 visits (1308 patients), and
3799 visits (1226 patients) for BLSA, InCHIANTI and WHAS, respectively.
WHAS combines the WHAS I and WHAS II studies, and is solely women
aged 65+. NHANES is a cross-sectional study based on a representative
sample of the US population and conducted in various waves since the
1970s; we combine data from six waves (1998–2007) which yielded a
sample of 29 188 patients. The analysis of semi-independence of
different aging systems was performed on all of the four datasets. The
effect of age on dysregulation was performed on the three longitudinal
datasets. The analysis of health outcomes were performed on InCHIANTI
and WHAS.
Biomarker selection
Biomarkers were chosen based on availability in sufficient sample size
across the four studies. In a few cases, biomarker groupings differed
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Fig. 4 Relationships between dysregulation scores and health outcomes. Estimations (points) together with 95% CIs (segments) for relationships between health outcomes
and dysregulation scores by physiological system, as well as global dysregulation scores. Results are based on regression models adjusting for age and sex. Different colors
indicate different systems. ‘W’ indicates Women’s Health and Aging Study (WHAS) and ‘I’ InCHIANTI. Associations between dysregulation scores and certain health
outcomes are stronger, while the association is more ambiguous for CVD and not significant for cancer.
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slightly across datasets due to data availability, but we assured the same
number of biomarkers per group in each dataset (Table 1). Due to
missing data, we did not include vitamins in the analyses of BLSA. Folate,
total vitamin D-25 and vitamin B12 were only available at baseline in
InCHIANTI, so we included these biomarkers in the cross-sectional
analysis of biomarker correlations between biomarker groups (Figs 1 and
2), but did not include them in the longitudinal analyses showing
associations between age and dysregulation scores and associations
between dysregulation scores and health outcomes (Figs 3 and 4). The
biomarkers are listed in Table 1 with their means and standard
deviations, organized by a priori physiological system. The need for a
largely common list of biomarkers across four datasets resulted in a final
list that was composed nearly exclusively of markers that are (i) common;
(ii) used often in clinic; and (iii) cheap, increasing the relevance of any
results for clinical implementation. Assignment of markers to a priori
systems was based on consultation among biologists on the team.
Dysregulation scores
Recently, we proposed a novel way to measure physiological dysregu-
lation based on clinical biomarkers (Cohen et al., 2013) and we use this
method to measure dysregulation in this paper. Under the hypothesis
that a well-functioning, homeostatic physiology should be relatively
similar across individuals, but that there are many ways in which
physiology might become dysregulated, we proposed statistical distance,
specifically Mahalanobis distance, (Mahalanobis, 1936) as a measure of
physiological dysregulation. The Mahalanobis distance applied to
biomarkers is a measure of how aberrant an individual’s profile is
relative to everyone else in the population, and greater distance should
thus measure greater dysregulation. The Mahalanobis distance also has
certain advantages over other multivariate distances. For example, the
Euclidean distance is a special case of the Mahalanobis distance when
variables are uncorrelated with each other (Tan et al., 2006); by taking
into account correlation structure, Mahalanobis distance automatically
corrects for redundancy among variables.
Normally, statistical distance is calculated based on the entire
population, but this is not optimal when it is interpreted as physiological
dysregulation, because the ‘normal’ state is defined as the centroid of
the entire population. Using a younger, healthier reference population to
calculate the centroid provides a better signal, though choice of
reference population is not critical unless it differs substantially from
the study population in multiple demographic characteristics (Cohen
et al., 2015a). Here, we used the younger patients as the reference
group, and calculated the Mahalanobis distance from each patient to the
centroid of the reference group in the multivariate biomarker space. Age
structure is different in the four datasets, so we took different age
thresholds for different datasets based on the principle that the
reference group should consist of relatively younger patients in each
dataset and sample size of the reference group should not be too small.
For NHANES we took patients under 45 years old as reference group, 55
for BLSA, 65 for InCHIANTI and 75 for WHAS. In each case we used the
biomarker values from the first visit of each eligible patient to make the
reference group. To confirm that results were not sensitive to choices of
age thresholds, we reran each model using two additional manually
chosen thresholds within 5 years of those listed above, but found no
qualitative differences in results (data not shown). This is expected based
on our previous validation study (Cohen et al., 2015a). The system-
specific dysregulation scores were compared with global dysregulation
scores based on all biomarkers.
Data analysis
Changes in dysregulation with age were studied using Bayesian linear
mixed models with uninformative priors and an individual intercept. We
first fitted the quadratic model; if the quadratic term was not significant
we fitted the linear model; and if the linear model was still not significant
we show a dashed line in the figure. Age started from 65 forWHAS (green
lines) whereas the other two datasets had some younger patients, though
they were still primarily composed of individuals aged 65+. All analyses
were performed in R v3.0.1. All codes are available upon request.
Data transformation
All biomarkers were transformed before analysis. The variables were log-
or square-root- transformed as necessary to approach normality. All
variables were centered at the mean of the reference group and divided
by the standard deviation of the reference group.
Correlation between dysregulation scores of a priori systems
Previous studies (Cohen et al., 2013, 2014; Milot et al., 2014b) showed
that global dysregulation increased with age, and the current study
confirms that this is also true for system-specific dysregulation (see
‘association of dysregulation with age’). Accordingly, correlations among
dysregulation scores of different systems might be due solely to the fact
that each correlates with age, rather than to an independent biological
link in the dysregulation rates. We thus adjusted for age before
measuring correlations between system-specific dysregulation scores.
We did this by calculating the residuals (predicted values) of the
dysregulation scores after running a locally weighted regression in each
case (R function loess()), since the change of dysregulation scores
with age is likely to be non-linear and we wanted to capture the full
relationship as faithfully as possible. We also replicated the analysis
without adjusting for the effect of age (Fig. S1).
Table 2 Significant temporal predictions of inter-system dysregulation scores identified using structural equations models
Baltimore longitudinal study on aging (5 systems) Women’s Health and Aging Study (5 systems) InChianti (5 systems) InChianti (6 systems)
Blood ? Electrolyte Lipid ? Blood Lipid ? Electrolyte Lipid ? Electrolyte
Electrolyte ? Lipid Electrolyte ? Liver Immune ? Blood Immune ? Blood
Liver ? Electrolyte Liver ? Electrolyte Blood ? Liver
Electrolyte ? Immune Vitamin ? Immune
Liver ? Vitamin
The signs of the two arrows ‘Lipid ? Electrolyte’ and ‘Immune ? Blood’ are negative. Relationships listed are those significant at a = 0.05, among the 20 tested in datasets
with five systems and 30 tested in datasets with six systems. Note that no relationship was replicated in more than two datasets, and only three (Liver ? Electrolyte,
Lipid ? Electrolyte, and Immune ? Blood) were replicated in two systems.
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For NHANES, we had only one visit per patient. For cross-sectional
analyses of the three longitudinal datasets, we randomly selected a
visit with complete data for each patient to eliminate intra-patient
correlations. For InCHIANTI, this corresponded exactly to the first visit
because several biomarkers were not taken during the follow-up visits.
We calculated the Pearson correlations among the age-adjusted
dysregulation scores as reported in Fig. 1. For example, the a priori
system of electrolytes contained five biomarkers and the a priori
system of vitamins consisted of seven biomarkers; we obtained the
age-adjusted dysregulation scores for the electrolyte system based on
the five biomarkers and the age-adjusted dysregulation scores for the
vitamin system based on the seven biomarkers. In this way, each
patient had two new variables, one representing dysregulation in the
electrolyte system and the other representing dysregulation in the
vitamin system, and we calculated the correlation between the two
variables to measure the dependence level between the two system-
specific dysregulation processes. This resulted in the ‘Electrolyte-
Vitamin’ correlation in Fig. 1.
As information on vitamins was largely unavailable for BLSA, we
decided not to include vitamin dysregulation for BLSA. For WHAS,
there was no patient with complete information on all 37 biomarkers,
so we reported pairwise correlations on available observations.
Correlations among all possible biomarker groupings
The same biomarkers were used to calculate correlations among age-
adjusted dysregulation scores of all possible combinatorial biomarker
groupings with equal size to the a priori biomarker groupings. There
are 6ð61Þ2 = 15 correlations among the six a priori biomarker groups.
For each of the 15 cases, we took all biomarkers in the two a priori
groups, divided them into two random biomarker groups with equal
size to the a priori groups, and calculated the correlation between the
dysregulation scores of the two random biomarker groups (represent-
ing system-specific dysregulation in two ‘random’ physiological
systems). We then repeated this for all combinatorial divisions of
the biomarkers into sets of appropriate size. Taking the same example
of electrolytes and vitamins, there are 12 biomarkers altogether from
the two a priori biomarker groups. Since the two a priori groups had
five and seven biomarkers respectively, we analyzed always of dividing
the 12 biomarkers into two groupings, one with five biomarkers and
the other with seven. As a result, there were C512 = 792 possibilities to
make two arbitrary biomarkers groupings having equal size with the
two original groups. In each of the 792 cases, we calculated age-
adjusted dysregulation scores based on the two arbitrary biomarker
groups, and then calculated the correlation between these two age-
adjusted dysregulation scores. This generated 792 correlation coeffi-
cients. We showed the four kernel density distributions for the four
datasets of the 792 correlations in the panel ‘Electrolyte-Vitamin’ in
Fig. 2; to compare with the a priori biomarker grouping, we also
showed the correlation between the a priori dysregulation scores with
vertical dotted lines; positions of the vertical dotted lines on the x-axis
indicate the correlations, i.e., the values presented in Fig. 1.
Association of dysregulation scores with age
Trajectories of dysregulation scores with age were estimated for each
physiological system, and also for the global dysregulation score
calculated with all of the 37 biomarkers, for the three datasets with
longitudinal information. We used Bayesian mixed models implemented
in R (package MCMCGLMM) with uninformative priors, 17 000 iterations
and burn-in at 7000, which was always sufficient to insure auto-
correlations in Markov chain samples of < 0.1. Models included
population- and individual-level intercept, age, and square of age at
each visit. Inclusion or exclusion of individual-level terms had little effect
on fixed effect estimates.
Association of health status with dysregulation scores
For InCHIANTI and WHAS, for which we had access to health status
information, we ran a series of regression models to predict health
status based on dysregulation scores controlling for age (and for sex
in InCHIANTI). Due to data availability, frailty was analyzed longitu-
dinally in WHAS and cross-sectionally in InCHIANTI, while chronic
diseases were analyzed longitudinally in InCHIANTI and cross-section-
ally in WHAS. The relationship between dysregulation scores and
mortality was assessed using time-to-event Cox proportional hazards
models with age as the timescale. Frailty criteria and number of
comorbidities were assessed using Poisson regression. Logistic regres-
sion was used for individual chronic diseases. Age was rigorously
controlled for using a flexible cubic basis spline (bs function, FDA
package, R) with four knots. The Poisson regressions and logistic
regressions were implemented with the MCMC Bayesian generalized
linear mixed model (MCMCGLMM package), when longitudinal data were
available, controlling for individual as a random effect. When the data
were cross-sectional, we used the glm() function. We tested the
relationship between each system’s dysregulation and each health
outcome both with and without control for dysregulation of all other
systems.
There are many other determinants of health status that we do not
control for, nonetheless, the notion of causality in complex dynamic
systems does not apply in the same way it does to simple, deterministic
systems (Wagner, 1999); accordingly, we were not attempting to show
even putative causal relationships between dysregulation scores and
health outcomes, but rather consistent and strong associations indicat-
ing a close linkage of the phenomena within network dynamics.
Structural equations models
To assess possible feedback effects among dysregulations in different
systems, we employed Seemingly Unrelated Regression (SUR; Zellner,
1962), a variant on structural equations models. These models permitted
us to test for the effects of each system on each other system,
controlling for the effects of all the other systems. Models used lagged
effects such that we were always assessing the effect of a dysregulation
level at a given visit on the level of another dysregulation level at the
subsequent visit. We were not able to use this longitudinal approach to
the vitamin system except for InCHIANTI.
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